세계의 유전자 편집 시장 보고서(2025년)
Gene Editing Global Market Report 2025
상품코드 : 1824526
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

유전자 편집 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 18.9%를 나타내 206억 2,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 치료 용도의 확대, 정밀성과 효율성의 향상, 유전자 치료의 상업화, 농업 용도의 개발, 재생 의료의 성장에 기인한다고 생각됩니다. 예측 기간의 주요 동향에는 다중 편집 기술, 염기 편집 혁신, 유전자 드라이브 및 집단 변형, 비바이러스 전달 시스템, 질병 모델링 및 의약품이 포함됩니다.

향후 5년간의 성장률 18.9%라고 하는 예측은 전회의 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 상승은 캐나다나 한국에서 조달하는 CRISPR-Cas9 시약과 전기천공장비의 비용을 끌어올려, 학술연구소의 예산 제약을 악화시켜, 유전성 질환의 잠재적 치료법을 지연시킴으로써, 미국의 의학 연구에 부담을 줄 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

전염병의 확산 증가는 유전자 편집 시장 성장의 원동력이 되고 있으며, 유전자 편집 기술은 이러한 질병의 검출과 치료에 필수적입니다. 전염병은 박테리아, 바이러스, 기생충과 같은 감염 인자로 인한 것으로, 사람과 동물 사이 또는 환경에 노출되어 퍼질 수 있습니다. 유전자 편집 기술은 유전자 수준에서 병원체를 확인하고 중화하기 위한 표적 방법을 개발하는데 점점 더 많이 사용되고 있으며, 그 결과 질병 관리와 예방이 강화됩니다. 예를 들어 2023년 스위스에 본사를 둔 국제 비정부기구인 세계경제 포럼은 유행기간 이후 인플루엔자와 호흡기 합포체 바이러스(RSV)와 같은 감염이 증가하고 있다고 보고했습니다. 미국에서는 2023년 2월까지 인플루엔자만으로 추정 2,400만명이 병을 앓고, 26만명이 입원, 1만 6,000명이 사망했습니다. 게다가 2022년 세계보건기구(WHO)는 세계에서 1,060만명이 결핵에 감염되어 130만명이 사망했다고 보고했습니다. 그 결과, 전염병의 만연이 유전자 편집 시장 성장에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Gene editing refers to the innovative technology enabling precise changes in the genetic code at specific locations within a genome. This cutting-edge process involves manipulating genetic material in various fields such as cell line engineering, animal genetic engineering, and plant genetic engineering.

The primary gene editing technologies include CRISPR, TALEN, and ZFN. CRISPR, a groundbreaking method, empowers geneticists and medical researchers to edit sections of the genome by altering, inserting, or removing DNA sequences accurately. These technologies find applications across biotechnology, pharmaceuticals, and contract research organizations, serving purposes in animal genetic engineering, plant genetic engineering, and cell line engineering.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The gene editing market research report is one of a series of new reports from The Business Research Company that provides gene editing market statistics, including gene editing industry global market size, regional shares, competitors with a gene editing market share, detailed gene editing market segments, market trends and opportunities, and any further data you may need to thrive in the gene editing industry. This gene editing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gene editing market size has grown rapidly in recent years. It will grow from $8.82 billion in 2024 to $10.31 billion in 2025 at a compound annual growth rate (CAGR) of 17.0%. The growth in the historic period can be attributed to discovery of crispr-cas9, advancements in genetic sequencing, medical breakthroughs, scientific research funding, biotechnology industry growth.

The gene editing market size is expected to see rapid growth in the next few years. It will grow to $20.62 billion in 2029 at a compound annual growth rate (CAGR) of 18.9%. The growth in the forecast period can be attributed to therapeutic applications expansion, precision and efficiency enhancements, gene therapy commercialization, agricultural applications development, regenerative medicine growth. Major trends in the forecast period include multiplex editing techniques, base editing innovations, gene drives and population modification, non-viral delivery systems, disease modeling and drug discovery.

The forecast of 18.9% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. medical research by driving up the cost of CRISPR-Cas9 reagents and electroporation equipment sourced from Canada and South Korea, exacerbating budget constraints for academic labs and delaying potential cures for genetic disorders. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of communicable diseases is driving growth in the gene editing market, as gene editing techniques become essential for the detection and treatment of these illnesses. Communicable diseases, which result from infectious agents like bacteria, viruses, or parasites, can spread between people, animals, or through environmental exposure. Gene editing technologies are increasingly used to create targeted methods for identifying and neutralizing pathogens at the genetic level, thus enhancing disease management and prevention. For example, in 2023, the World Economic Forum, a Switzerland-based international non-governmental organization, reported an increase in infections such as influenza and respiratory syncytial virus (RSV) since the pandemic. In the USA, by February 2023, influenza alone led to an estimated 24 million illnesses, 260,000 hospitalizations, and 16,000 deaths. Additionally, in 2022, the World Health Organization reported that 10.6 million people worldwide were infected with tuberculosis, resulting in 1.3 million deaths. Consequently, the prevalence of communicable diseases is fueling the growth of the gene editing market.

The global gene editing market is expected to witness growth due to the rising incidence of genetic disorders. Genetic disorders result from abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. These disorders can lead to various health issues, either present at birth or developing later in life. Gene editing offers substantial potential in addressing severe genetic diseases such as sickle cell disease, Huntington's disease, B-thalassemia, cystic fibrosis, Alzheimer's, and Parkinson's. For example, the National Library of Medicine (NLM) reported an estimated 6.7 million Americans aged 65 and older living with Alzheimer's dementia (AD) in 2023. The prevalence is projected to increase to 13.8 million by 2060 unless medical breakthroughs intervene. Genetic disorders are on the rise, and the application of gene editing technologies is expected to drive market growth.

Infectious diseases continue to pose a significant threat globally, causing more than 17 million deaths annually, as reported by the World Health Organization (WHO). Public sentiment reflects the growing acceptance of gene editing for the treatment of incurable, hereditary diseases, with 71% of surveyed adults in the US expressing support for its use, according to the AP-NORC survey. Additionally, 67% of Americans endorse gene editing for disease prevention, including conditions such as cancer. This positive perception underscores the potential of gene editing technologies in addressing various health challenges and contributing to market growth.

Major companies are introducing innovative technologies, such as a technique based on special cell-penetrating peptides, which offers advantages over existing methods. In April 2023, Penn Medicine, a prominent US-based multi-hospital health system, discovered that protein fragments used by certain viruses to enter cells could also facilitate the efficient and low-toxicity delivery of CRISPR-Cas gene editing molecules into cells and their DNA-containing nuclei. This breakthrough holds potential for developing advanced cell therapies for diseases such as cancer. The technique is particularly promising for modifying T cells and other patient-derived cells for applications such as CAR T (chimeric antigen receptor T cell) therapy, a specialized immunotherapy for cancer treatment. This new genetic engineering approach promises improvements in speed, efficiency, and reduced cellular toxicity compared to current methods.

The emergence of advanced genome editing techniques stands out as a major trend in the gene editing market. These techniques, characterized by their cost-effectiveness, find applications in diverse fields, including agriculture to enhance the food supply, rectifying specific genetic mutations in the human genome, and preventing the spread of diseases. One notable genome editing technique is CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats), known for its role as molecular scissors that make precise cuts in DNA at specific locations to create space for incorporating new genetic material. CRISPR-Cas9 offers advantages in terms of speed, cost-efficiency, accuracy, and overall effectiveness compared to other existing genome editing methods. Companies such as Crispr Therapeutics (CRSP), Intellia Therapeutics (NTLA), and Editas Medicine are actively investing in CRISPR technology, reflecting the significant impact and potential of this cutting-edge gene editing approach.

In February 2024, Ginkgo Bioworks, a US-based biotechnology company, acquired Patch Biosciences for an undisclosed sum. This acquisition is a significant step in Ginkgo's strategy to strengthen its genetic medicine capabilities, aiming to integrate Patch's AI-driven platform with Ginkgo's current services, including gene therapy, cell therapy, and RNA therapeutics. This move aligns with Ginkgo's broader strategy of expanding its portfolio through acquisitions, particularly of companies focused on molecular medicine and AI-driven drug discovery. Patch Biosciences, a US-based biotechnology company, specializes in gene editing and the development of genetic medicines.

Major companies operating in the gene editing market include AstraZeneca plc, Thermo Fisher Scientific Inc., Merck KGaA, GE Healthcare Life Sciences, Agilent Technologies Inc., Lonza Group AG, PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., CRISPR Therapeutics, Promega Corporation, GenScript USA Inc., Integrated DNA Technologies Inc., Intellia Therapeutics Inc., DNA Script Inc., Dharmacon Inc., Precision Biosciences Inc., Editas Medicine Inc., OriGene Technologies Inc., Tecan Group Ltd., Sangamo Therapeutics Inc., Horizon Discovery Group plc, Addgene Inc., New England Biolabs Inc., Cellectis SA, Recombinetics Inc., Allele Biotechnology LLC, Transposagen Biopharmaceuticals Inc., Bluebird Bio Inc., Regeneron Pharmaceuticals Inc., Amsbio LLC, Creative Biogene Inc., Synthego Corporation, Beam Therapeutics Inc., Caribou Biosciences Inc., Inscripta Inc., Mammoth Biosciences Inc., Sangon Biotech (Shanghai) Co. Ltd., ToolGen Inc., Mirus Bio LLC

North America was the largest region in the gene editing market in 2024. Western Europe was the second largest region in the global gene editing market share. The regions covered in the gene editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gene editing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The gene editing market includes revenue earned by zinc-finger nucleases (ZFNs) and homing endonucleases or meganucleases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gene Editing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gene editing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for gene editing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gene editing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Gene Editing Market Characteristics

3. Gene Editing Market Trends And Strategies

4. Gene Editing Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gene Editing Growth Analysis And Strategic Analysis Framework

6. Gene Editing Market Segmentation

7. Gene Editing Market Regional And Country Analysis

8. Asia-Pacific Gene Editing Market

9. China Gene Editing Market

10. India Gene Editing Market

11. Japan Gene Editing Market

12. Australia Gene Editing Market

13. Indonesia Gene Editing Market

14. South Korea Gene Editing Market

15. Western Europe Gene Editing Market

16. UK Gene Editing Market

17. Germany Gene Editing Market

18. France Gene Editing Market

19. Italy Gene Editing Market

20. Spain Gene Editing Market

21. Eastern Europe Gene Editing Market

22. Russia Gene Editing Market

23. North America Gene Editing Market

24. USA Gene Editing Market

25. Canada Gene Editing Market

26. South America Gene Editing Market

27. Brazil Gene Editing Market

28. Middle East Gene Editing Market

29. Africa Gene Editing Market

30. Gene Editing Market Competitive Landscape And Company Profiles

31. Gene Editing Market Other Major And Innovative Companies

32. Global Gene Editing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gene Editing Market

34. Recent Developments In The Gene Editing Market

35. Gene Editing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기